Clinical Trials Logo

Clinical Trial Summary

Sugammadex is a new reversal agent for neuromuscular blockers (curare). It encapsulates the curare molecule and terminates immediately its action. The recommended dose is 2 mg/kg for a slight neuromuscular block and 4 mg/kg for a profound neuromuscular block. Magnesium sulphate is frequently used in perioperative medicine and it is known to reinforce the neuromuscular block induced for instance by rocuronium. The researchers want to investigate, whether higher doses of sugammadex must be given to antagonize the neuromuscular block induced by rocuronium in patients who received magnesium sulphate.


Clinical Trial Description

Neuromuscular blocking agents (NMBAs) are frequently used in anaesthesia and intensive care medicine for tracheal intubation, artificial ventilation, and continued muscle relaxation during surgical interventions. Postoperative residual curarisation is associated with an increased risk of postoperative complications and morbidity. Consequently, adequate reversal of neuromuscular block after surgery is of great importance.

Cholinesterase inhibitors have been widely used as reversal agents. They increase the amount of acetycholine at the neuromuscular junction, which then competes with the NMBA to restore muscle function. Cholinesterase inhibitors have, however, a number of limitations. They antagonise the neuromuscular block slowly and are only effective when partial spontaneous recovery has already occurred. These agents are also associated with a relatively high incidence of cholinergic adverse reactions, including bradycardia, arrhythmia, salivation, and bronchoconstriction.

Sugammadex, a modified gamma cyclodextrin, is a selective binding agent specifically designed to encapsulate steroidal NMBAs such as rocuronium. It causes a rapid and complete reversal of neuromuscular blockade by preventing directly rocuronium to react on the neuromuscular receptor.

Dose-finding studies have suggested that sugammadex 2 mg kg-1 was needed for the reversal of a moderate neuromuscular block (reappearance of T2), and that doses ≥4 mg kg-1 were needed for the reversal of a profound block (1 to 2 post-tetanic counts). The median time for the recovery of a moderate neuromuscular block to a T4/T1 ratio of 0.9 (which is considered clinically safe) is around two minutes, and of a profound neuromuscular block is about three minutes.

Magnesium is sometimes used in perioperative medicine, for instance, to prevent seizures in parturients with pre-eclampsia. Magnesium has an impact on neuromuscular transmission. It reduces the amount of acetylcholine that is released at the motor nerve terminal, by decreasing the calcium conductance of presynaptic voltage-dependent calcium channels. After pre-treatment with a clinically relevant dose of magnesium sulphate (MgSO4), an increased speed of onset and a prolongation of the recovery period of the neuromuscular blockade have been observed with standard intubation doses of atracurium, vecuronium, and rocuronium. With rocuronium, for instance, the investigators recorded a shortening of the speed of onset of the neuromuscular block by about 35% but at the expense of a prolongation of the recovery period by about 25%. It has been shown that the interaction between magnesium and rocuronium may become relevant in specific clinical situations.

The clinically relevant interaction between MgSO4 and rocuronium begs the question as to whether in a patient who has received MgSO4, the efficacy of sugammadex to reverse a rocuronium-induced block may be affected. Indeed, animal studies have indicated that significantly higher doses of sugammadex might be needed to reverse a rocuronium-induced neuromuscular block after magnesium pretreatment.

The aim of this study is to test the hypothesis that the established doses of sugammadex for the fast and safe reversal of a moderate and a profound rocuronium-induced neuromuscular block are inadequate in patients who have received MgSO4. The investigators hypothesize that in subjects who received magnesium pretreatment, the time to reverse a moderate and a deep neuromuscular block (induced by a single intubation dose of rocuronium) with standard doses of sugammadex (2 and 4 mg kg-1, respectively) is prolonged by ≥ 50% and that the dose response curves will be displaced to the right (i.e. higher doses of sugammedex will be necessary to achieve the same speed of action as in patients who are not exposed to magnesium. ;


Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment


Related Conditions & MeSH terms


NCT number NCT01440933
Study type Interventional
Source University Hospital, Geneva
Contact
Status Completed
Phase Phase 2
Start date September 2011
Completion date June 2012

See also
  Status Clinical Trial Phase
Completed NCT02484651 - Can Adequacy of Anesthesia Depth and Quality of Recovery be Influenced by the Level of Neuromuscular Blockade? Phase 4
Recruiting NCT02778945 - Neuromuscular Blockade for Optimising Surgical Conditions During Spinal Surgery Phase 4
Recruiting NCT02966249 - Dexmetomidine Intrathecally and Intravenously Additionally to Spinal Anaesthesia, in Total Knee Arthroplasty Phase 4
Completed NCT02838134 - Deep Versus Moderate Muscle Relaxation During Laparoscopic Donor Nephrectomy in Enhancing Postoperative Recovery Phase 4
Completed NCT03734250 - D Vitamin Effects on Neuromuscular Blocker Reverse Time
Not yet recruiting NCT03287388 - MRI Measurement of the Effects of Deep Neuromuscular Blockade on the Abdominal Working Space During Laparoscopy N/A
Completed NCT01791036 - Adductor Canal Block In Anterior Cruciate Ligament (ACL) Repair N/A
Not yet recruiting NCT02648503 - Deep Neuromuscular Block and Sugammadex Versus Standard of Care on Quality of Recovery in Patient Undergo Elective Laparoscopic Cholecystectomy Phase 4
Completed NCT00895609 - Sugammadex and Neostigmine at Shallow Neuromuscular Blockade Phase 4
Completed NCT02483611 - Effects of Intravenous Lidocaine Associated With Magnesium Sulfate on the Cisatracurium-Induced Neuromuscular Block Phase 4
Completed NCT02320734 - Deep Neuromuscular Relaxation in Patients for Thoraco-laparoscopic Esophagectomy Phase 4
Recruiting NCT05005676 - Evaluation of the New Acceleromyograph TOF 3D N/A
Not yet recruiting NCT03460509 - Reversal With Low Doses of Sugammadex in Patients Undergoing Non-cardiac Surgery Phase 4
Completed NCT00828373 - The Influence of Intravenous Lidocaine on the Action of the Neuromuscular Blocker Rocuronium Phase 4